Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool July 22, 2009 Robert Steyer	Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry.
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
The Motley Fool August 1, 2008 Brian Orelli	Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit.
The Motley Fool October 29, 2009 Robert Steyer	Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle.
The Motley Fool January 13, 2011 Brian Orelli	This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars.
The Motley Fool June 15, 2006 Brian Gorman	Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool July 27, 2011 Michael Olsen	Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment.
The Motley Fool January 25, 2007 Brian Gorman	Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.
The Motley Fool April 20, 2011 Brandon Glenn	Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool November 30, 2007 Brian Orelli	Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way.
The Motley Fool January 27, 2005 Brian Gorman	Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results.
The Motley Fool October 21, 2005 Brian Gorman	Covance Keeps Delivering Investors seemed to fret over the drug-development services company's full-year earnings forecast, but the facts suggest that Covance remains a solid long-term bet.
The Motley Fool April 27, 2010 Brian Orelli	Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home.
The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
The Motley Fool January 27, 2006 Brian Gorman	Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet.
The Motley Fool October 1, 2008 Brian Orelli	WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
The Motley Fool January 14, 2011 Brian Orelli	Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing.
The Motley Fool October 30, 2006 Brian Gorman	Quality in Covance Some investors are pulling back from the company's stock, but Covance will continue to deliver.
The Motley Fool July 22, 2011	Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again.
The Motley Fool August 27, 2011 Michael Olsen	Rising Star Buy: More Icon Icon shares might not appreciate tomorrow, and they might decline more before they go up. But here is a rare value: a secular growth story at a stellar valuation.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
The Motley Fool April 28, 2006 Brian Gorman	Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note.
The Motley Fool August 13, 2009 Brian Orelli	WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year.
Chemistry World November 12, 2014 Phillip Broadwith	Labcorp to buy Covance and enter contract research Medical diagnostics specialist Labcorp has agreed to buy contract research organization Covance for around $6 billion.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
Pharmaceutical Executive December 1, 2012 Torrey et al.	Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.
The Motley Fool September 8, 2004 Charly Travers	Will a Clinical Trial Database Help Investors? While this development is certainly good news for patients and physicians, the impact on investors may be minimal, depending upon the type of data that will be released.
Pharmaceutical Executive April 1, 2009 David Zuckerman	Make a Match Big Pharma is finally making a commitment to partner-based outsourcing.
The Motley Fool February 10, 2005 Stephen D. Simpson	eResearch Regains Heartbeat Increased FDA and consumer worries about cardiac safety should continue to fuel the cardiac researcher's growth.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
Chemistry World February 18, 2010 Matt Wilkinson	Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut.
The Motley Fool April 25, 2005 Brian Gorman	Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar.
The Motley Fool August 25, 2006 Brian Gorman	California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool June 7, 2005 Brian Gorman	Covance Under Fire The contract research company could suffer at the hands of the animal-rights group PETA. The value of a company's public image is hard to quantify. For investors, this is definitely a case worth watching.
The Motley Fool June 25, 2008 Brian Orelli	WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play?
The Motley Fool December 29, 2006 Brian Lawler	Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology.
The Motley Fool June 4, 2009 Brian Orelli	MegaMergers Going to the Dogs It looks like Merck isn't sure it'll be able to get its acquisition of Schering-Plough past regulators without doing a little trimming.